Form 4 for DGX Quest Diagnostics
Accepted 2024-02-16 00:00:00 ET · period of report 2024-02-14 · accession 0001022079-24-000036 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-16 | 2024-02-14 | DGX | Davis J. E. | CEO, Pres, Dir | A - Grant | $0.00 | +22.3K | 124.9K | +22% | $0 |
| D | 2024-02-16 | 2024-02-14 | DGX | Davis J. E. | CEO, Pres, Dir | A - Grant | $0.00 | +92.8K | 92.8K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-14 | A | A | 22,251 | $0.00 | 124,885 | D | — | — | (F1) Represents an award of restricted share units. |
| 2 | Derivative | Non-Qualifed Stock Option (right to buy) | 2024-02-14 | A | A | 92,779 | $0.00 | 92,779 | D | $127.81 · — to 2034-02-14 | 92,779 Common Stock | (F2) The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. |